No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Pharmaceuticals
PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injection, a brown ampoule containing a pale yellow transparent liquid; ZADAXIN injection, an adjunctive therapy for influenza vaccination in immunocompromised elderly patients; PLACENTEX injection for the treatment and tissue restoration of wounds; CLEVIEL VOLUME to temporarily improve facial wrinkles in adults through the physical restoration; Rejuran HB plus which is used for temporary improvement of adult's crow's feet wrinkles; Rejuvenex injection, a tissue regeneration activator that regenerates connective tissues, including ligament, tendon, skin, etc.; and Rejuvenex cream, which treats the wound through rapid tissue regeneration. It also provides REJURAN, a medical device for face (especially eye, perioral area), neck, Décolleté, hands, etc; CLEVIEL prime plus and contour plus with lidocaine medical devices; D+CELL 350 TRA I; and REJURAN moisturizer for daily skin protection, as well as REJUVENEX SCULPT V; REJURAN concentrate for sensitive and aged skin; REJURAN healing eye gel and mask; REJURAN sunscreen that protects skin from UV rays; and REJURAN recover soothing mask. In addition, the company offers D+CELL 350 TRA concentrated rejuvenation cream, intensive repair serum, activating facial toner, high potency eye lift, moisture balancer, mask, hair, cream, and hydro products; REJURAN tone-up booster; REJURAN FORTE; and CONJURAN medical devices. Further, it offers functional foods; and engages in the development of software and consulting businesses. The company was formerly known as Pharma Research Products Co., Ltd. and changed its name to PharmaResearch Co., Ltd. in April 2021. PharmaResearch Co., Ltd. was founded in 1993 and is headquartered in Gangneung-si, South Korea.
pharmaresearch.co.krNo one on the platform currently holds 214450.KQ.
No tracked institution reports a position in 214450.KQ as of their last filing.
No one on the platform has traded 214450.KQ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 22.6% | 18.8% | 13.1% | — | — | — |
| Rev. Growth % | 53.0% | 37.6% | ||||
| Profit Margin % | 30.8% | 27.5% | 26.4% | |||
| Free Cash Flow Margin % | 28.7% | 25.0% | 11.3% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $698.5B | +29.2% | $20115.91 | $19143.66–$21285.39 | — | 11 |
| 2027 | $846.6B | +21.2% | $24584.75 | $18791.88–$28175.80 | — | 14 |
| 2028 | $1.01T | +19.0% | $29766.72 | $26633.66–$31705.37 | — | 7 |
| 2029 | $1.19T | +18.2% | $0.00 | $0.00–$0.00 | — | 7 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 5 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-07 | $4043.92 | $4043.92 | +0.0% |
| 2026-05-08 | $3557.03 | $3733.32 | +5.0% |
| 2026-02-04 | $3686.32 | $2583.38 | -29.9% |
| 2025-11-11 | $3697.19 | $4234.13 | +14.5% |
| 2024-11-14 | $2508.09 | $1860.00 | -25.8% |
| +1.51% |
| $2.54T |
| — |
| 226950.KQOliX Pharmaceuticals,Inc | $108300.00 | +8.19% | $2.20T | — |
| 302440.KSSK bioscience Co.,Ltd. | $36750.00 | -2.78% | $2.88T | — |
Source: Financial Modeling Prep · peers by sector/industry